高级检索
当前位置: 首页 > 详情页

High HOXA9 gene expression predicts response to chemotherapy and prognosis of high-grade serous ovarian cancer patients

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ 预警期刊

机构: [1]Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China [2]Department of Intensive Care Unit, Hebei Medical University, Fourth Hospital, Shijiazhuang, China
出处:
ISSN:

关键词: Homeobox A9 high-grade serous ovarian cancer expression resistance prognosis clinical study

摘要:
ObjectiveHigh-grade serous ovarian cancer (HGSOC) is a deadly malignancy. Homeobox protein A9 (HOXA9) is linked with serous papillary histotype differentiation, and inappropriate HOXA9 expression is a step in ovarian cancer that induces aberrant differentiation. This study aimed to reveal the significance of HOXA9 in HGSOC. MethodsHOXA9 mRNA and protein expression were examined by quantitative PCR and immunohistochemistry, respectively. The chi-square test was used to evaluate associations between HOXA9 expression and clinical characteristics. The prognostic value of HOXA9 was calculated by the Kaplan-Meier method. The Kaplan-Meier Plotter database was used to assess the prognostic value of HOXA9. ResultsThe mRNA and protein expression of HOXA9 were significantly upregulated in chemotherapy-resistant HGSOC compared with chemotherapy-sensitive HGSOC. The chi-square test showed that high HOXA9 expression was significantly related with grade, clinical stage, and residual disease. High HOXA9 expression was significantly associated with poor prognosis. The Kaplan-Meier Plotter database further confirmed these results. Cox hazard regression showed that high HOXA9 expression was an independent prognostic factor for survival in HGSOC patients. ConclusionThis study showed that HOXA9 expression was associated with chemotherapy resistance and poor outcomes in HGSOC patients. High HOXA9 expression might be a prognostic indicator for HGSOC.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 药学 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
JCR分区:
出版当年[2022]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China [*1]Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Jian kang lu 12, Shijiazhuang 050011, China
通讯作者:
通讯机构: [1]Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China [*1]Department of Obstetrics and Gynecology, Hebei Medical University, Fourth Hospital, Jian kang lu 12, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号